U.S. FDA Approval of FRUZAQLAâ„¢... | 09-Nov-2023 | 07:00 | RNS |
Vesting of awards under the LTIP | 24-Oct-2023 | 09:30 | RNS |
Total Voting Rights | 29-Sep-2023 | 09:30 | RNS |
Director’s Share Dealing | 14-Sep-2023 | 09:30 | RNS |
Total Voting Rights | 31-Aug-2023 | 09:30 | RNS |
Sovleplenib Phase 3 Study Meets Primary Endpoint | 21-Aug-2023 | 07:00 | RNS |
Exercise of Share Options by a Director | 07-Aug-2023 | 09:30 | RNS |
Interim Results and Business Updates | 31-Jul-2023 | 12:00 | RNS |
Changes to Board and Technical Committee | 13-Jul-2023 | 09:30 | RNS |
Blocklisting Six Monthly Return | 29-Jun-2023 | 09:30 | RNS |
HUTCHMED to Announce 2023 Half-Year Results | 26-Jun-2023 | 09:30 | RNS |
Phase III FRESCO-2 Results in The Lancet | 16-Jun-2023 | 07:00 | RNS |
MAA of Fruquintinib Validated by the EMA | 15-Jun-2023 | 15:39 | RNS |
LTIP and Share Option Scheme | 06-Jun-2023 | 10:00 | RNS |
Total Voting Rights | 31-May-2023 | 09:30 | RNS |
Currency | UK Pounds |
Share Price | 324.00p |
Change Today | -13.00p |
% Change | -3.86 % |
52 Week High | 352.00 |
52 Week Low | 173.60 |
Volume | 104,366 |
Shares Issued | 871.26m |
Market Cap | £2,822.87m |
RiskGrade | 226 |
Value |
---|
Price Trend |
---|
Income |
---|
Growth |
---|
No dividends found |
Time | Volume / Share Price |
16:35 | 4,472 @ 324.00p |
16:35 | 1,744 @ 324.00p |
16:35 | 256 @ 324.00p |
16:35 | 861 @ 324.00p |
16:35 | 271 @ 324.00p |
You are here: research